Castration Resistant Prostate Cancer:
Mastering New Therapies

Program Overview

To optimize treatment of patients with castration resistant prostate cancer, physicians need clear, balanced guidance from experts in the field on several important topics, including:

• New research on androgen signaling and implications for defining and treating castration resistant disease;
• New therapies for castration resistant disease and how they fit into the existing treatment framework;
• Relevant case examples, including discussion of options, timing, duration and sequence of treatment.

Four webcasts presented by leaders in prostate cancer research and treatment will review recent advances and current practice on specific topics, and discuss best practice in the context of case presentations.

Module 1: Androgen Signaling & Hormone Blockade in CRPC
Module 2: Immunotherapy Today & Tomorrow
Module 3: New Approaches to Chemotherapy in CRPC
Module 4: Treatment & Prevention of Bone Metastases

Target Audience: This program is designed for physicians and other medical professionals involved in the clinical care of patients with prostate cancer.

Faculty Listing:
Philip W. Kantoff, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

A. Oliver Sartor, MD
Tulane University School of Medicine
New Orleans, Louisiana

Matthew R. Smith, MD, PhD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Module 1: Androgen Signaling & Hormone Blockade in CRPC
Credit Hours	Credit Type
1.0	AMA PRA

 

Module 2: Immunotherapy Today & Tomorrow
Credit Hours	Credit Type
1.0	AMA PRA

 

Module 3: New Approaches to Chemotherapy in CRPC
Credit Hours	Credit Type
1.0	AMA PRA

 

Module 4: Treatment & Prevention of Bone Metastases
Credit Hours	Credit Type
1.0	AMA PRA

 

[Back to top]

[Back to Activity Home]